Phaseline

Companies › ML Bio Solutions

ML Bio Solutions: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Neurology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BBP-418
substrate supplementation to enhance glycosylation of muscle α-dystroglycan
FKRPPhase 3Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I); LGMD2INov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04800874BBP-418Phase 2LGMD2INeurologyNov 2026
NCT05775848BBP-418Phase 3Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)NeurologySep 2027
NCT07678775BBP-418Phase 3Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)NeurologyOct 2030

Targets

FKRP (1)

Companies with the same targets

AskBio Atamyo Therapeutics

Companies built like this

Bigespas JYAMS PET Research & Development Longboard Pharmaceuticals TriGemX Bio Zogenix

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.